Nonavalent Human Papillomavirus Vaccine as a Treatment for Recalcitrant Warts in an Adult with HIV
Main Article Content
Keywords
human papillomavirus, immunosuppressed, vaccine, wart, HIV, nonavalent, gardasil
Abstract
To the Editor: Cutaneous warts are seen in as many as a quarter of immunosuppressed patients. 1 Cell-mediated immunodeficiency, as seen in HIV, is correlated with increased rates of palmoplantar warts. 2 These warts often cause discomfort, and can progress to verrucous carcinoma. As they can be resistant to traditional treatments like cryotherapy, patients must resort to more aggressive and invasive measures like intralesional bleomycin. In this case report, we present an immunocompromised patient with HIV successfully treated for his palmoplantar human papilloma virus (HPV) warts using the nonavalent HPV vaccine (Gardasil 9TM, Merck Inc, Kenilworth, NJ, USA) after only marginal improvement with six treatments of bleomycin.
References
2. Leto M, Santos Júnior GF, Porro AM, Tomimori J. Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations. An Bras Dermatol. Mar-Apr 2011;86(2):306-17. doi:10.1590/s0365-05962011000200014
3. King CM, Johnston JS, Ofili K, et al. Human papillomavirus types 2, 27, and 57 Identified in plantar verrucae from HIV-positive and HIV-negative individuals. J Am Podiatr Med Assoc. Mar 2014;104(2):141-6. doi:10.7547/0003-0538-104.2.141
4. Whitaker JM, Palefsky JM, Da Costa M, King CM, Johnston JS, Barbosa P. Human papilloma virus type 69 identified in a clinically aggressive plantar verruca from an HIV-positive patient. J Am Podiatr Med Assoc. Jan-Feb 2009;99(1):8-12. doi:10.7547/0980008
5. Ferguson SB, Gallo ES. Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult. JAAD Case Rep. Jul 2017;3(4):367-369. doi:10.1016/j.jdcr.2017.05.007
6. Smith SP, Baxendale HE, Sterling JC. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Clin Exp Dermatol. Apr 2017;42(3):306-308. doi:10.1111/ced.13038
7. Silling S, Wieland U, Werner M, Pfister H, Potthoff A, Kreuter A. Resolution of novel human papillomavirus-induced warts after HPV vaccination. Emerg Infect Dis. Jan 2014;20(1):142-5. doi:10.3201/eid2001.130999
8. Kreuter A, Waterboer T, Wieland U. Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination. Arch Dermatol. Oct 2010;146(10):1196-7. doi:10.1001/archdermatol.2010.290
9. Waldman A, Whiting D, Rani M, Alam M. HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults: A Retrospective Cohort Study. Dermatol Surg. Dec 2019;45(12):1739-1741. doi:10.1097/dss.0000000000001867
10. Landis MN, Lookingbill DP, Sluzevich JC. Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine. J Am Acad Dermatol. Aug 2012;67(2):e73-4. doi:10.1016/j.jaad.2011.08.022
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.